Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04105517
Other study ID # RECHMPL19_0402
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2019
Est. completion date October 30, 2019

Study information

Verified date November 2020
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Infantile hemangioma is a benign tumor belonging to the group of vascular tumors in the ISSVA classification (International Society for the Study of Vascular Anomalies). The diagnosis is clinical and radiological. The hemangioma appears during the first weeks of life (70% classically within 2 weeks after birth) but can, when it develops in the subcutaneous tissue, appear until the age of 2 to 3 months . Its evolution is characteristic and is divided into 3 phases with a proliferative phase characterized by a rapid increase in the size of the tumor (up to 6 to 12 months), a phase of stabilization (from 12 to 36 months) with a stopping of the growth of the hemangioma and a regression of its size and a phase of involution with the disappearance of the lesion which may give way to residual fibroadipose tissue, cutaneous telangiectases, scars … The usual complications of haemangiomas occur during the proliferative phase. It is necrosis, ulcerations that can be complicated by bleeding or infection and eventually indelible scarring. Other complications related to the site of development of hemangiomas (amblyopia, astigmatism, upper respiratory obstruction, nasal obstruction, sphincter disorders, eating disorders), hemangiomas destroying structures noble (breast hypodévelopment, alopecia). The aesthetic prognosis can be seriously compromised for facial locations. Historically, when drug therapy was required, patient management was based on systemic corticosteroids (at doses of 3 to 5 mg / kg / day) in first-line therapy and vincristine as a second-line failure of corticosteroid therapy or when life-threatening is at stake. In 2014, the high French health authority (HAS) gave Marketing Authorization for Hemangiol 3.75 mg / ml oral solution for the management of infantile proliferative hemangioma requiring first-line systemic treatment, evaluating the actual benefit as important. The selected indication concerns children from 5 weeks to 5 months with: - Hemangiomas leading to a vital or functional risk, - Hemangiomas ulcerated painful and / or not responding to simple care, - Hemangiomas with a risk of permanent scarring or disfigurement. The 2014 HAS Transparency Commission wishes in its report "to have follow-up data of prescriptions allowing to describe on a representative sample of patients, the characteristics of the treated patients, the indication, the doses and the durations of treatment of this specialty ". The objective of our study is to describe the use of Hemangiol in current practice in our hospital from 2014 to 2018.


Description:

This study is retrospective, longitudinal, descriptive and observational. Children aged 0 to 1 years hospitalized for introduction of Hemangiol between January 2014 and November 2018 will be included. Patients refuse the use of medical data will be excluded. The main objective is to describe the population who received Hemangiol. The secondary objectives is to evaluate - the effectiveness of Hemangiol on proliferative infantile hemangiomas, -the tolerance of Hemangiol in children with proliferative infantile hemangiomas - the interest of systematic cardiological consultation in children with proliferative infantile hemangiomas receiving Hemangiol The following criteria will be collected Demographic description: age, sex, height, weight Personal history Description of the hemangioma: - organ concerned: skin, liver, parotid, mixed. - location: head, thorax, pelvis, limbs, diffuse ... - single or multiple - indication of treatment: aesthetic, functional, ulcerated, cardiac hyperacidity Rhythm of follow-up: duration of treatment and observance of treatment Prescribed dose: 1, 2, 3 or 4 mg / kg / day in 2 doses Evolution of the hemangioma: progression, regression, stagnation. Needed a second medical therapeutic line by specifying the treatment introduced. Necessity of surgical management by specifying the delay between surgery and the introduction of treatment Description of serious adverse events: hypotension, bradycardia, bronchospasm, hypoglycaemia. Description of other adverse events. Number of cardio-pediatric consultations, specifying: - incidence of diagnosed heart disease through systematic cardiac consultation - effect on ECG data of increasing dosage of Hemangiol: heart rate, PR duration, QRS duration, QT duration


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date October 30, 2019
Est. primary completion date October 20, 2019
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion criteria: - Child from 0 to 18 years old hospitalized for introduction of Hemangiol between January 2014 and November 2018 Exclusion criteria: - Patients refuse the use of medical data will be excluded.

Study Design


Locations

Country Name City State
France Uh Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

References & Publications (1)

Socchi F, Bigorre M, Normandin M, Captier G, Bessis D, Mondain M, Blanchet C, Akkari M, Amedro P, Gavotto A. Hemangiol in infantile haemangioma: A paediatric post-marketing surveillance drug study. Br J Clin Pharmacol. 2020 Oct 28. doi: 10.1111/bcp.14593. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events in children with proliferative infantile hemangiomas receiving Hemangiol rate serious adverse events: hypotension, bradycardia, bronchospasm, hypoglycemia
rate of adverse events
6 days
Secondary Incidence of the regression of proliferative infantile hemangiomas in children receiving Hemangiol rate of regression of the hemangioma
rate of need for a second therapeutic medical line
rate of need for surgical management
6 days
Secondary Incidence of diagnosed heart diseases with systematic cardiac consultation events in children with proliferative infantile hemangiomas receiving Hemangiol rate of diagnosed heart disease 3 days
See also
  Status Clinical Trial Phase
Completed NCT02505971 - Nadolol Versus Propranolol in Children With Infantile Hemangiomas Phase 3
Recruiting NCT04288700 - Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma Phase 4
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT01010308 - Nadolol for Proliferating Infantile Hemangiomas Phase 2
Completed NCT02913612 - Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) Phase 2
Completed NCT01673971 - Optical Tomographic Imaging of Infantile Hemangiomas
Recruiting NCT03237637 - Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Phase 3
Recruiting NCT05479123 - Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas Phase 4
Terminated NCT01434849 - Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial) Phase 1
Completed NCT01512173 - Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo Phase 2
Completed NCT01056341 - Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy Phase 2/Phase 3
Not yet recruiting NCT04684667 - ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma" Phase 2
Recruiting NCT03842631 - Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
Recruiting NCT03173352 - A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China N/A